2023
Onconephrology: Core Curriculum 2023
Yarandi N, Shirali A. Onconephrology: Core Curriculum 2023. American Journal Of Kidney Diseases 2023, 82: 743-761. PMID: 37855786, DOI: 10.1053/j.ajkd.2023.04.014.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsKidney diseaseChimeric antigen receptor T cellsAntigen receptor T cellsAJKD's Core CurriculumAcute kidney injuryKidney transplant recipientsChronic kidney diseaseReceptor T cellsKidney injuryTransplant recipientsElectrolyte disordersCell transplantClinical syndromeMonoclonal gammopathyGlomerular diseaseT cellsCancer riskClinical decisionCancer treatmentDiseaseOnconephrologySyndromeCancerSpecific considerationsHypertensionHow Sweet It Is: A Perspective on the Potential Anti-Tumor Role for SGLT2 Inhibitors
Gunasekaran D, Shirali A. How Sweet It Is: A Perspective on the Potential Anti-Tumor Role for SGLT2 Inhibitors. Kidney360 2023, 4: e1322-e1324. PMID: 37487034, PMCID: PMC10550005, DOI: 10.34067/kid.0000000000000219.Commentaries, Editorials and LettersOnco-Nephrology Kidney Disease in the Cancer Patient
Yarandi N, Shirali A. Onco-Nephrology Kidney Disease in the Cancer Patient. Medical Clinics Of North America 2023, 107: 749-762. PMID: 37258012, DOI: 10.1016/j.mcna.2023.03.007.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsKidney diseaseAcute kidney injuryChronic kidney diseaseDifferent clinical manifestationsSubspecialty of nephrologyOnco-NephrologyKidney injuryElectrolyte disturbancesClinical manifestationsCancer patientsGeneral internistsPatientsDiseaseCancerHypertensionProteinuriaInternistsInjuryNephrologyChemotherapy-Associated Thrombotic Microangiopathy
Aklilu A, Shirali A. Chemotherapy-Associated Thrombotic Microangiopathy. Kidney360 2023, 4: 409-422. PMID: 36706238, PMCID: PMC10103319, DOI: 10.34067/kid.0000000000000061.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsMeSH KeywordsAntineoplastic AgentsGemcitabineHumansNeoplasmsProteasome InhibitorsThrombotic MicroangiopathiesConceptsDrug-induced thrombotic microangiopathyThrombotic microangiopathyPlasma exchangePrimary atypical hemolytic uremic syndromeAtypical hemolytic uremic syndromeEnd-organ dysfunctionMicroangiopathic hemolytic anemiaSecondary thrombotic microangiopathyTherapeutic plasma exchangeTerminal complement inhibitorLarge multicenter studyHemolytic uremic syndromeRole of complementPotential treatment strategyProteinuria reductionSupportive careBlood pressureMulticenter studyTreatment courseUremic syndromeComplement inhibitionTreatment strategiesHemolytic anemiaAntiangiogenesis agentsComplement inhibitors
2022
Cancer Drug Dosing in Chronic Kidney Disease and Dialysis
Shirali AC, Sprangers B. Cancer Drug Dosing in Chronic Kidney Disease and Dialysis. Advances In Kidney Disease And Health 2022, 29: 208-216.e1. PMID: 35817528, DOI: 10.1053/j.ackd.2021.12.002.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsChronic kidney diseaseKidney diseaseKidney functionEnd-stage kidney diseasePatient's kidney functionRenal replacement therapyCurrent dosing strategiesClassic chemotherapeutic drugsReplacement therapyDosing strategiesHigh prevalenceDrug dosingKidney metabolismAntineoplastic agentsPharmacokinetic propertiesChemotherapeutic drugsDiseaseSpecific agentsPatientsDosingTherapyDrugsAgentsImmunotherapyMalignancy